BiOS
Cheaper. Faster.
Right the first time.
We help companies make innovative medicines at a cost the world can carry — so more patients get them, on time.
Ultimately: heal the world.
Why it matters
When batches fail, COGS stays high, and capacity is short, everyone pays.
On the company books
Failed lots burn materials and suite time. High cost of goods eats margin and blocks access. Limited capacity means you cannot supply the demand your science created. That is bottom-line damage — and it compounds every campaign.
On the patient path
The same failures become higher treatment cost, delays to the clinic, and shortages on the shelf. A medicine that only a few can afford, or that arrives too late, does not heal the world.
How BiOS works
Make the operating system keep up with the science.
Process, materials, quality, capacity, and ownership have to move together. BiOS builds working tools and fixed-fee assessments so leadership can freeze the right decisions — across antibodies, cell therapy, viral vector, and small-molecule API.
- CheaperCOGS analysis that shows which levers actually move the bill.
- FasterLine balance, release, and scale-up decisions that clear the critical path.
- Right first timeQuality and compliance built into the plan, not bolted on after a failure.
The point
Every lot that releases on cost, on time, and right first time is a patient who can be treated.
That is the mission. The tools on this site — COGS analysis, Line Balance Lab, the readiness scorecard, and the Operational Scale-Up Assessment — are how we start.